CA2070664A1 - Inhibition du papillomavirus au moyen d'un oligonucleotide antisens - Google Patents

Inhibition du papillomavirus au moyen d'un oligonucleotide antisens

Info

Publication number
CA2070664A1
CA2070664A1 CA2070664A CA2070664A CA2070664A1 CA 2070664 A1 CA2070664 A1 CA 2070664A1 CA 2070664 A CA2070664 A CA 2070664A CA 2070664 A CA2070664 A CA 2070664A CA 2070664 A1 CA2070664 A1 CA 2070664A1
Authority
CA
Canada
Prior art keywords
papillomavirus
oligonucleotide
oligonucleotides
antisense oligonucleotide
oligonucleotide inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2070664A
Other languages
English (en)
Other versions
CA2070664C (fr
Inventor
Christopher K. Mirabelli
David J. Ecker
Lex M. Cowsert
Stanley T. Crooke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Christopher K. Mirabelli
David J. Ecker
Lex M. Cowsert
Isis Pharmaceuticals, Inc.
Stanley T. Crooke
Isis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Christopher K. Mirabelli, David J. Ecker, Lex M. Cowsert, Isis Pharmaceuticals, Inc., Stanley T. Crooke, Isis Pharmaceuticals Inc. filed Critical Christopher K. Mirabelli
Publication of CA2070664A1 publication Critical patent/CA2070664A1/fr
Application granted granted Critical
Publication of CA2070664C publication Critical patent/CA2070664C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/708—Specific hybridization probes for papilloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oligonucléotides et analogues oligonucléotidiques pouvant avoir une action réciproque non codante avec l'ARN messager du virus du papillome. De tels oligonucléotides ou analogues oligonucléotidiques peuvent servir au diagnostic et à la thérapeutique ainsi qu'à des fins de recherche. Selon des modes de réalisation préférés, l'oligonucléotide ou l'analogue oligonucléotidique est hybridable avec un ARN messager provenant d'un virus du papillome, peut inhiber la fonction de l'ARN, et est donc utile à la thérapie des infections provoquées par un tel virus du papillome. Selon un mode de réalisation préféré, on cible des parties du virus du papillome pour une attaque non codante. On peut donc obtenir les oligonucléotides préférables, c'est-à-dire ceux qui s'hybrident avec les ARN messagers E2, E1, E7, ou E6-7.
CA002070664A 1989-12-04 1990-12-03 Inhibition du papillomavirus au moyen d'un oligonucleotide antisens Expired - Fee Related CA2070664C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44519689A 1989-12-04 1989-12-04
US445,196 1989-12-04
PCT/US1990/007067 WO1991008313A1 (fr) 1989-12-04 1990-12-03 Inhibiteurs oligonucleotidiques non codants du virus du papillome

Publications (2)

Publication Number Publication Date
CA2070664A1 true CA2070664A1 (fr) 1991-06-05
CA2070664C CA2070664C (fr) 2000-08-08

Family

ID=23767951

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002070664A Expired - Fee Related CA2070664C (fr) 1989-12-04 1990-12-03 Inhibition du papillomavirus au moyen d'un oligonucleotide antisens

Country Status (11)

Country Link
EP (1) EP0503002B1 (fr)
JP (1) JPH05501058A (fr)
KR (1) KR960012069B1 (fr)
AT (1) ATE163973T1 (fr)
AU (1) AU650257B2 (fr)
BR (1) BR9007892A (fr)
CA (1) CA2070664C (fr)
DE (1) DE69032134T2 (fr)
FI (1) FI922593A (fr)
HU (1) HUT62944A (fr)
WO (1) WO1991008313A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447839A (en) * 1988-09-09 1995-09-05 Hoffmann-La Roche Inc. Detection of human papillomavirus by the polymerase chain reaction
US5457189A (en) * 1989-12-04 1995-10-10 Isis Pharmaceuticals Antisense oligonucleotide inhibition of papillomavirus
US5620963A (en) * 1991-10-15 1997-04-15 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
US6339066B1 (en) 1990-01-11 2002-01-15 Isis Pharmaceuticals, Inc. Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US5587361A (en) * 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5635488A (en) * 1991-10-15 1997-06-03 Isis Pharmaceuticals, Inc. Compounds having phosphorodithioate linkages of high chiral purity
US5599797A (en) * 1991-10-15 1997-02-04 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5576302A (en) * 1991-10-15 1996-11-19 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
US5661134A (en) * 1991-10-15 1997-08-26 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
US5654284A (en) * 1991-10-15 1997-08-05 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
US5607923A (en) * 1991-10-15 1997-03-04 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
US6537973B1 (en) 1992-03-16 2003-03-25 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
WO1995028942A1 (fr) * 1994-04-26 1995-11-02 Genta Incorporated Oligomeres non codants utilises pour inhiber les virus du papillome humains
US5750341A (en) * 1995-04-17 1998-05-12 Lynx Therapeutics, Inc. DNA sequencing by parallel oligonucleotide extensions
US6509149B2 (en) * 1995-06-06 2003-01-21 Hybridon, Inc. HPV-specific oligonucleotides
US6458940B2 (en) * 1995-06-06 2002-10-01 Hybridon, Inc. HPV-specific oligonucleotides
FR2758725B1 (fr) * 1997-01-29 1999-04-02 Pasteur Institut Composition comprenant une proteine e2 de papillomavirus ou une sequence de nucleotides codant pour une proteine e2 de papillomavirus
EP2212420A2 (fr) * 2007-11-05 2010-08-04 Baltic Technology Development, Ltd. Utilisation d'oligonucléotides avec des bases modifiées comme agents antiviraux

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
WO1988006634A1 (fr) * 1987-02-26 1988-09-07 The University Of Sydney Procede de detection de papillomavirus humains carcinogenes
US4849332A (en) * 1987-05-26 1989-07-18 Life Technologies, Inc. Human papillomavirus 35 nucleic acid hybridization probes and methods for employing the same
US4849331A (en) * 1987-06-09 1989-07-18 Life Technologies, Inc. Human papillomavirus 44 nucleic acid hybridization probes and methods for employing the same
US4849334A (en) * 1987-06-09 1989-07-18 Life Technologies, Inc. Human papillomavirus 43 nucleic acid hybridization probes and methods for employing the same
US4908306A (en) * 1987-06-12 1990-03-13 Life Technologies, Inc. Human papillomavirus 56 nucleic acid hybridization probes and methods for employing the same
FR2629458B2 (fr) * 1987-07-31 1991-08-09 Ire Celltarg Sa Nouvelles sondes d'acides nucleiques specifiques de differents types de virus de papillome humain
US4886741A (en) * 1987-12-09 1989-12-12 Microprobe Corporation Use of volume exclusion agents for the enhancement of in situ hybridization
DE3838269A1 (de) * 1988-11-11 1990-05-17 Behringwerke Ag Nachweis humaner papillomavirus dna und ihrer expression in zervix-abstrichen
US5027693A (en) * 1989-11-24 1991-07-02 Allied-Signal Inc. Combination diaphragm and valve body
AU7302191A (en) * 1990-01-30 1991-08-21 Children's Hospital Of Los Angeles Inhibition of transcription by double-stranded oligonucleotides

Also Published As

Publication number Publication date
BR9007892A (pt) 1992-09-29
ATE163973T1 (de) 1998-03-15
CA2070664C (fr) 2000-08-08
EP0503002A1 (fr) 1992-09-16
KR960012069B1 (ko) 1996-09-12
JPH05501058A (ja) 1993-03-04
HUT62944A (en) 1993-06-28
WO1991008313A1 (fr) 1991-06-13
FI922593A0 (fi) 1992-06-04
EP0503002A4 (en) 1993-03-10
DE69032134D1 (de) 1998-04-16
FI922593A (fi) 1992-06-04
DE69032134T2 (de) 1998-07-23
AU7175691A (en) 1991-06-26
HU9201865D0 (en) 1992-09-28
EP0503002B1 (fr) 1998-03-11
AU650257B2 (en) 1994-06-16

Similar Documents

Publication Publication Date Title
EP0637316A4 (fr) Inhibition du virus du papillome a l'aide d'oligonucleotides non codants.
CA2070664A1 (fr) Inhibition du papillomavirus au moyen d'un oligonucleotide antisens
HU9501963D0 (en) 7-deazapurine modified oligonucleotides
EP0977767A4 (fr) Oligonucleotides modifies par aminooxy
AU4072089A (en) Inhibition of htlv-iii by exogenous oligonucleotides
WO1987007300A3 (fr) Inhibition de l'htlv-iii par des oligonucleotides exogenes
BR9206156A (pt) Oligonucleotídeo ou análogo de aligonucleotídeo processo de modular a expressão do gene H-RAS humano processo de detectar a presença do gene H-RAS em células ou em tecidos processo de detectar H-RAS ativado baseado na afinidade diferencial de oligonucleotídeos particulares por H-RAS ativado VS,tipo,processo de tratar condicões que surgem da ativacão do oncogene H-RAS
WO2006047842A3 (fr) Nucleosides modifies pour interference arn
AU8771398A (en) Novel hiv-specific synthetic oligonucleotides and methods of their use
AU2022295A (en) Nucleic acid amplification with DNA-dependant RNA polymerase activity of RNA replicases
WO2001002423A3 (fr) Oligomeres fonctionnalises et a base de guanidine
HUP0103465A2 (hu) A VEGF expressziójának gátlására szolgáló rövid oligonukleotidok
WO2001032832A3 (fr) Modulation antisens de l'expression de la nucleoline
EP0425995A3 (en) Use of conserved oligonucleotide primers to amplify human papillomavirus dna sequences
AU3295700A (en) Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same
AP1674A (en) The genome of the HIV-1 inter-subtype (C/B') and use thereof.
ES2112062T3 (es) Oligonucleotidos con actividad anti-citomegalovirus.
ES2048652A1 (es) Procedimientos de amplificacion de genoma para la deteccion e identificacion de secuencias genomicas relacionadas.
NO922169L (no) Antisensoligonukleotidinhibisjon av papillomavirus
WO1995030748A3 (fr) Sequences u14 d'acide nucleique de vegetaux et leurs derives
WO2006123800A3 (fr) Element d'induction d'interference arn et son utilisation

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed